Paxalisib

DRUG8 trials

Sponsors

Prinses Maxima Centrum voor Kinderoncologie B.V., Global Coalition for Adaptive Research, Lakshmi Nayak, MD, University of California, San Francisco, Weill Medical College of Cornell University

Conditions

Atypical Teratoid/Rhabdoid Tumor (ATRT) of the CNSChildhood Brain TumorChildhood CancerChildhood Solid TumorDiffuse Intrinsic Pontine GliomaDiffuse Midline Glioma, H3 K27M-MutantDiffuse Midline Gliomas (DMGs) including Diffuse Intrinsic Pontine Gliomas (DIPGs)Glioblastoma

Phase 1

Optimal Precision TherapIes to CustoMISE Care in Childhood and Adolescent Cancer

RecruitingNCT06208657

Australian & New Zealand Children's Haematology/Oncology GroupChildhood Brain Tumor, Childhood Cancer, Childhood Solid Tumor +2

Start: 2024-07-10End: 2035-12-01Target: 90Updated: 2026-01-28

5G-PEARL: Paxalisib in Malignant Brain Tumours

RecruitingNCT07391215

Institute of Cancer Research, United KingdomGlioblastoma Multiforme (GBM), Malignant Primary Gliomas

Start: 2026-01-19End: 2029-06-30Target: 64Updated: 2026-02-05

Phase 2

A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma

RecruitingNCT03970447

Global Coalition for Adaptive ResearchGlioblastoma

Start: 2019-07-30End: 2030-06-01Target: 2250Updated: 2026-04-03

Paxalisib (GDC-0084) In Recurrent Or Refractory PCNSL

RecruitingNCT04906096

Lakshmi Nayak, MDNon-Hodgkin Lymphoma of Extranodal Site, Primary Central Nervous System Lymphoma

Start: 2021-06-01End: 2027-12-01Target: 25Updated: 2025-06-26

Combination Therapy for the Treatment of Diffuse Midline Gliomas

RecruitingNCT05009992

University of California, San FranciscoDiffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, H3 K27M-Mutant, Recurrent Diffuse Intrinsic Pontine Glioma +3

Start: 2021-10-20End: 2029-06-30Target: 360Updated: 2025-12-17

Paxalisib With a High Fat, Low Carb Diet and Metformin for Glioblastoma

SuspendedNCT05183204

Weill Medical College of Cornell UniversityGlioblastoma

Start: 2022-02-14End: 2026-06-30Target: 33Updated: 2025-12-18

PNOC022: A Combination Therapy Trial using an Adaptive Platform Design for Children and Young Adults with Diffuse Midline Gliomas (DMGs) including Diffuse Intrinsic Pontine Gliomas (DIPGs) at Initial Diagnosis, Post-Radiation Therapy and at Time of Progression

SuspendedCTIS2023-507598-16-00

Prinses Maxima Centrum voor Kinderoncologie B.V.Diffuse Midline Gliomas (DMGs) including Diffuse Intrinsic Pontine Gliomas (DIPGs)

Start: 2022-10-20Target: 30Updated: 2025-08-21

Study of Novel Therapies for Young People With Recurrent/Progressive Atypical Teratoid Rhabdoid Tumor (ATRT)

Not yet recruitingNCT07447076

Sabine Mueller, MD, PhDAtypical Teratoid/Rhabdoid Tumor (ATRT) of the CNS, Recurrent Atypical Teratoid/Rhabdoid Tumor

Start: 2026-05-01End: 2036-12-31Target: 29Updated: 2026-03-03

Related Papers

EXTH-89. Precision Targeting of PI3K/mTOR in Diffuse Midline Glioma: GCT007 as a Novel Brain-Penetrant PIK3CA Inhibitor

Neuro-Oncology2025-11-01

TIP-10. Update on GBM AGILE: A global, phase 2/3 adaptive platform trial to evaluate multiple regimens in newly diagnosed and recurrent glioblastoma

Neuro-Oncology2025-11-01

Update on GBM AGILE: A global, phase 2/3 adaptive platform trial to evaluate multiple regimens in newly diagnosed and recurrent glioblastoma.

Journal of Clinical Oncology2025-05-281 citations

Abstract A044: Immune profiling tools for adult and pediatric cancer: From whole genome and transcriptome sequencing to immunotherapy clinical trial design

Cancer Research2025-03-11

Omnigene-Gut<sup>tm</sup> ensures fecal microbiome stability in the pediatric population.

2024-12-06

LTBK-02. EVALUATION OF PAXALISIB IN GBM AGILE PHASE 3 REGISTRATION PLATFORM TRIAL FOR NEWLY DIAGNOSED AND RECURRENT GLIOBLASTOMA

Neuro-Oncology2024-11-012 citations

CTNI-39. UPDATE ON GBM AGILE: A GLOBAL, PHASE 2/3 ADAPTIVE PLATFORM TRIAL TO EVALUATE MULTIPLE REGIMENS IN NEWLY DIAGNOSED AND RECURRENT GLIOBLASTOMA

Neuro-Oncology2024-11-01

OS09.7.A GBM AGILE PLATFORM TRIAL FOR NEWLY DIAGNOSED AND RECURRENT GBM: RESULTS OF FIRST EXPERIMENTAL ARM, REGORAFENIB

Neuro-Oncology2024-10-012 citations

KS03.5.A EVALUATION OF VAL-083 IN GBM AGILE, A PHASE 3 REGISTRATION PLATFORM TRIAL FOR NEWLY DIAGNOSED AND RECURRENT GLIOBLASTOMA

Neuro-Oncology2024-10-01

P27.11.A GLOBAL EXPANSION OF GBM AGILE: A PHASE 2/3 ADAPTIVE PLATFORM TRIAL TO EVALUATE MULTIPLE REGIMENS IN NEWLY DIAGNOSED AND RECURRENT GLIOBLASTOMA

Neuro-Oncology2024-10-01

Abstract B015: Transcriptome-based assessment of immune infiltration for molecular selection of pediatric patients with solid tumors for combination immune checkpoint inhibitor therapy

Cancer Research2024-09-05

Abstract B066: Bridging patient reported outcomes and CTCAE to improve supportive care and trial design: The PROptimise initiative

Cancer Research2024-09-05

Evaluation of VAL-083 in GBM AGILE, a phase 3 registration platform trial for newly diagnosed and recurrent glioblastoma.

Journal of Clinical Oncology2024-06-011 citations

Phase 1 dose expansion and biomarker study assessing first-in-class tumor microenvironment modulator VT1021 in patients with advanced solid tumors

Communications Medicine2024-05-216 citations

Rational combination platform trial design for children and young adults with diffuse midline glioma: A report from PNOC

Neuro-Oncology2023-12-202 citations

CTNI-85. GBM AGILE PLATFORM TRIAL FOR NEWLY DIAGNOSED AND RECURRENT GBM: RESULTS OF FIRST EXPERIMENTAL ARM, REGORAFENIB

Neuro-Oncology2023-11-0117 citations

EXTH-36. COMBINING ONC201 AND PAXALISIB FOR THE TREATMENT OF DIFFUSE MIDLINE GLIOMA (DMG); THE PRECLINICAL RESULTS UNDERPINNING THE INTERNATIONAL PHASE II CLINICAL TRIAL (NCT05009992)

Neuro-Oncology2023-11-01

EXTH-31. EXPLOITING THE GENETIC DEPENDENCY ON PI3K/MTOR SIGNALING FOR THE TREATMENT OF H3-ALTERED DIFFUSE MIDLINE GLIOMA

Neuro-Oncology2023-11-01

P11.29.B UPDATE ON GBM AGILE: A GLOBAL, PHASE 2/3 ADAPTIVE PLATFORM TRIAL TO EVALUATE MULTIPLE REGIMENS IN NEWLY DIAGNOSED AND RECURRENT GLIOBLASTOMA

Neuro-Oncology2023-09-01

Immune profiling in patients with glioblastoma treated with VT1021 in a phase I/II expansion study.

Journal of Clinical Oncology2023-06-013 citations

15 more papers not shown